Study drug KL002 for advanced Parkinson’s disease
Part of Brain & nervous system clinical trials.
This early-phase trial tests how safe and potentially effective KL002 is for people with advanced Parkinson’s disease. It may help reduce Parkinson’s movement symptoms, but the main early goal is safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 40 to 70 (men or women)
- Have Parkinson’s disease caused by idiopathic (not secondary) Parkinson’s, stage 4–5
- Have had Parkinson’s for at least 5 years
- Be able to do required study visits and follow-up (show good adherence)
- Your Parkinson’s movement score must be within a specific range when symptoms are “OFF” (about 25 to 60)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether injecting special cells into the brain can improve Parkinson's symptoms. It is for people who have had Parkinson's for at least 5 years, take levodopa but still have times when the medication wears off or causes uncontrolled movements.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests an investigational drug called IPS101A in people with advanced Parkinson's disease. It aims to see if the drug is safe and how well it works when standard treatments are no longer enough.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.